ZivastThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

• By Date
• Specialty Filter
• Discussions
• Top 20

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  

Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions  Atorvastatin prevented mucosal damage and inflammation associated with 5-FU-induced OM, but the association of a higher dose of ATV with 5-FU induced hepatotoxicity and amplified leukopenia. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1409-7Authors C. A. C. X. Medeiros, State University of Rio Grande do Norte Department of Biomedical Sciences Mossoró BrazilR. F. C. Leitão, Faculty of Medicine, Federal University of Ceará Department of Morphology Rua Delmiro de Farias, sn Fortaleza CE 60430-270 BrazilR. N. Macedo, Federal University of Ceará Department o...
Source: Cancer Chemotherapy and Pharmacology - July 26, 2010 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Atorvastatin/clarithromycin/simvastatin: Rhabdomyolysis and neuropathy: 2 case reportsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - July 25, 2010 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Atorvastatin: Myalgia in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - July 25, 2010 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Atorvastatin/simvastatin/fusidic acid interaction: Rhabdomyolysis: 4 case reportsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - July 25, 2010 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Atorvastatin/simvastatin: Muscle weakness in a patient with myasthenia gravis: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - July 23, 2010 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Atorvastatin/simvastatin: Myalgia and elevated creatine kinase levels: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - July 23, 2010 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Effects of Lipid-Lowering Therapy on Reduction of Cardiovascular Events in Patients with End-Stage Renal Disease Requiring HemodialysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pharmacotherapy 30(8): 823-829 Abstract In the general population, dyslipidemia is an established independent risk factor for cardiovascular disease. In patients with end-stage renal disease (ESRD), comorbid cardiovascular disease is present at alarming rates, and those who require hemodialysis and have cardiovascular disease continue to have a high mortality rate. Lipid abnormalities associated with chronic kidney disease (CKD) vary depending on the stage of disease (stages 1-5), but low-density lipoprotein cholesterol (LDL) has been established as the primary lipid treatment target. Guidelines support an LDL level of les...
Source: Pharmacotherapy: Official Journal of the American College of Clinical Pharmacy - July 23, 2010 Category: Drugs & Pharmacology Authors: Joel C MarrsJoseph J Saseen Source Type: journals

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Previous studies have demonstrated that benefits of intensive statin therapy compared to standard statin therapy begin shortly after an acute event and are continued up to 2 years of follow-up. However, whether efficacy and safety of intensive statin therapy in patients with a recent cardiac event are maintained in longer-term follow-up has not been evaluated. We conducted a post hoc analysis of a subgroup of 999 patients who had a first acute myocardial infarction (MI) (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - July 21, 2010 Category: Cardiology Authors: Terje R. Pedersen, Nilo B. Cater, Ole Faergeman, John J.P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Ingar Holme, Mogens Lytken Larsen, Christina Lindahl, Michael Szarek Tags: Coronary Artery Disease Source Type: journals

LIPITOR (Atorvastatin Calcium) Tablet, Film Coated [Physicians Total Care, Inc]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Jul 20, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 20, 2010 Category: Drugs & Pharmacology Source Type: organizations

End-stage renal diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New option(s) added for: Statins in people with end-stage renal disease and normal lipid profiles: New option for which we found one systematic review and two RCTs. The systematic review found no significant difference between statins and placebo in all-cause mortality and cardiovascular mortality, but reported that statins significantly reduced non-fatal cardiovascular events. The first RCT found that atorvastatin significantly reduced the composite outcome of all cardiac events (cardiovascular mortality, non-fatal MI, and interventions to treat coronary heart disease) compare...
Source: Clinical Evidence - July 20, 2010 Category: Journals (General) Source Type: journals

Open access status will be applied to atorvastatin in New Zealand later this year, following a 90% price reductionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 15, 2010 Category: Health Management Tags: Short communication Source Type: journals

Pfizer Announces European Union Approval Of A New Form Of Lipitor (atorvastatin) For Use In ChildrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pfizer Inc. (NYSE: PFE) announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 14, 2010 Category: Consumer Health News Tags: Cholesterol Source Type: news

Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: We have shown that intensive statin therapy started at admission in ACS patients has a highly significant, immediate effect on all monitored lipid levels. Since TC and LDL levels were decreased as predicted, reduction in HDL and increase in TG levels suggest a different acute effect of high-dose statin on lipid levels in comparison with long-term treatment of ACS patients. (Source: Lipids in Health and Disease)
Source: Lipids in Health and Disease - July 14, 2010 Category: Lipidology Authors: Dagmar VondrakovaPetr OstadalAndreas Kruger Source Type: journals

N.S. cholesterol drug costs to drop 50%Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The most commonly prescribed drug in Nova Scotia will soon be 50 per cent cheaper when a generic version of Lipitor becomes available in a month. (Source: CBC | Health)
Source: CBC | Health - July 13, 2010 Category: Consumer Health News Source Type: news

Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A rapid, simple, sensitive and specific LC-MS/MS method has been developed and validated for the simultaneous estimation of atorvastatin (ATO), amlodipine (AML), ramipril (RAM) and benazepril (BEN) using nevirapine as an internal standard (IS). The API-4000 LC-MS/MS was operated under the multiple-reaction monitoring mode using electrospray ionization. Analytes and IS were extracted from plasma by simple liquid-liquid extraction technique using ethyl acetate. The reconstituted samples were chromatographed on C(18) column by pumping 0.1% formic acid-acetonitrile (15:85, v/v) at a flow rate of 1 mL/min. A detailed valida...
Source: Biomedical Chromatography : BMC - July 13, 2010 Category: Biomedical Science Authors: Pilli NR, Inamadugu JK, Mullangi R, Karra VK, Vaidya JR, Seshagiri Rao JV Tags: Biomed Chromatogr Source Type: journals

Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The findings illustrated the challenges that will be encountered in designing efficacy studies to test the potential beneficial effects of atorvastatin in human HCM. (Source: European Journal of Clinical Investigation)
Source: European Journal of Clinical Investigation - July 12, 2010 Category: Journals (General) Authors: Sherif F. Nagueh, Raffaella Lombardi, Yanli Tan, Jianwen Wang, James T. Willerson, Ali J. Marian Source Type: journals

Ezetimibe reduces ox-LDL levelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Adding ezetimibe to atorvastatin decreases levels of oxidized low-density lipoprotein cholesterol in patients with coronary heart disease or an equivalent condition, research shows. (Source: MedWire News - Lipidology)
Source: MedWire News - Lipidology - July 10, 2010 Category: Lipidology Source Type: news

Pfizer Gets Approval For Lipitor For KidsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The European Union has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol. (Source: WDSU.com - Health)
Source: WDSU.com - Health - July 9, 2010 Category: Consumer Health News Authors: WDSU.com Source Type: news

Statin Lowers Cardiac Events in Diabetics on Hemodialysis With High Cholesterol LevelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Atorvastatin reduced cardiac events and overall mortality in diabetics on hemodialysis with the highest baseline levels of LDL cholesterol; the number needed to treat to reduce 1 event was 3. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 8, 2010 Category: Consumer Health News Tags: Nephrology News Source Type: news

Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract  Whole brain irradiation (WBI) is commonly administered therapeutically and is routinely associated with late delayed radiation injuries, manifesting as severe and irreversible cognitive impairment. Neural progenitors within the subgranular zone (SGZ) of the dentate gyrus are among the most radiosensitive cell types in the adult brain and are known to participate in hippocampal plasticity and normal cognitive function. These progenitors and the specialized SGZ microenvironment required for neuronal differentiation are the source of neurogenic potential in the adult dentate gyrus, and provide a contin...
Source: Journal of Neuro-Oncology - July 8, 2010 Category: Cancer & Oncology Tags: Journal of Neuro-Oncology Source Type: journals

Health Affairs: Modifying generic med substitution laws could slash almost $100MEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
With patent expiries for major name brand pharmaceutical drugs—Lipitor (atorvastatin; Pfizer), Plavix (clopidogrel; Sanofi-Aventis/Bristol-Myers Squibb) and Zyprexa (olanzapine; Eli Lilly)—on the horizon, switching to generic drug forms could save $100 million in Medicaid coverage costs. However, strict state generic substitution laws often require prior consent or step therapy approaches and make switching to generic brands difficult and costly, according to the results of a study published in the July edition of Health Affairs. (Source: Cardiovascular Business News)
Source: Cardiovascular Business News - July 8, 2010 Category: Cardiology Tags: Latest News Source Type: news

EU approves Pfizer's Lipitor drugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The European Union has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol and triglycerides (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 8, 2010 Category: Drugs & Pharmacology Source Type: news

Pediatric chewable Lipitor approved by EUEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pfizer has received European Union approval for a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes. (Source: Cardiovascular Business News)
Source: Cardiovascular Business News - July 7, 2010 Category: Cardiology Tags: Latest News Source Type: news

The Combination of Interferon-Beta and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SUMMARY Recent studies support the notion that statins, widely prescribed cholesterol-lowering agents, may target key elements in the immunological cascade leading to inflammation and tissue damage in the pathogenesis of multiple sclerosis (MS). Compelling experimental and observational clinical studies highlighted the possibility that statins may also exert immunomodulatory synergy with approved MS drugs, resulting in several randomized clinical trials testing statins in combination with interferon-beta (IFN-beta). Some data, however, suggest that this particular combination may not be clinically beneficial, and might...
Source: CNS Neuroscience and Therapeutics - July 7, 2010 Category: Neuroscience Authors: Sellner J, Weber MS, Vollmar P, Mattle HP, Hemmer B, Stüve O Tags: CNS Neurosci Ther Source Type: journals

Effect of Ezetimibe/Atorvastatin Combination on Oxidized Low Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease or Coronary Artery Disease EquivalentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to investigate the effect of ezetimibe on ox-LDL. A total of 100 patients with coronary artery disease or coronary artery disease equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to atorvastatin 40 mg/day and placebo. LDL cholesterol, LDL cholesterol subfractions, and ox-LDL were measured at baseline and after 8 weeks of therapy. The ezetimibe group had a larger reduction in total LDL cholesterol compared to placebo. This was due mainly to a larger reduction in large buoyant LDL (24% vs 10%, p = 0.008). Ox-LDL level did not change in the placebo group (50 ± 13...
Source: The American Journal of Cardiology - July 6, 2010 Category: Cardiology Authors: Rabih R. Azar, Georges Badaoui, Antoine Sarkis, Mireille Azar, Herminé Aydanian, Serge Harb, Guy Achkouty, Roland Kassab Tags: Coronary Artery Disease Source Type: journals

PLANET I and II: Atorvastatin beats rosuvastatin for protecting kidneys in diabetic and nondiabetic patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Two related trials suggest that the two statins have different effects on urinary protein excretion, with atorvastatin seemingly protective, and rosuvastatin exerting no protective effects, and... For complete story visit theheart.org. (Source: theHeart.org)
Source: theHeart.org - July 5, 2010 Category: Cardiology Source Type: info

Atorvastatin Beats Rosuvastatin in Protecting Kidneys in Diabetic and Nondiabetic PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The 2 PLANET trials show that atorvastatin reduces proteinuria and protects kidney function and that rosuvastatin does not in diabetic and nondiabetic patients with moderate proteinuria. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2010 Category: Consumer Health News Tags: Nephrology News Source Type: news

Preventing intraperitoneal adhesions with atorvastatin and sodium hyaluronate/carboxymethylcellulose: a comparative study in ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These data suggest that atorvastatin, administered intraperitoneally, is as effective as HA/CMC without an expectable additive effect in preventing postoperative adhesions in rats. (Source: American Journal of Surgery)
Source: American Journal of Surgery - July 1, 2010 Category: Surgery Authors: Miltiadis A. Lalountas, Konstantinos D. Ballas, Christos Skouras, Christos Asteriou, Theodoros Kontoulis, Dimitrios Pissas, Apostolos Triantafyllou, Athanasios K. Sakantamis Tags: Scientific (EXP) / Research Source Type: journals

Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of prediabetes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. The presence of prediabetes potentiates metabolic syndrome-induced abnormalities in plasma markers of inflammation, hemostasis, and in monocyte secretory function. Both atorvastatin and fenofibrate exhibit multidirectional pleiotropic effects in subjects with metabolic syndrome, the strength of which seems to be partially determined by the type of prediabetes. PMID: 20587704 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - June 29, 2010 Category: Endocrinology Authors: Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B Tags: Diabetes Care Source Type: journals

Patient with pontine warning syndrome and bilateral posterior internuclear ophthalmoplegia: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: 1) Pontine warning syndrome may be underestimated and understudied. 2) Posterior internuclear ophthalmoplegia is a rare clinical sign in cerebrovascular diseases, while it can help to locate a brainstem lesion rather than an internal capsular one. 3) Blood pressure lowing administration may be improper for patients with pontine warning syndrome. (Source: BMC Neurology)
Source: BMC Neurology - June 28, 2010 Category: Neurology Authors: Hai Wei HuangShen Wen HeShuang Quan TanLi Li Su Source Type: journals

Common Variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 Genes as Predictors of Lipid-Lowering Response to Atorvastatin TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DNA and Cell Biology , Vol. 0, No. 0. (Source: DNA and Cell Biology)
Source: DNA and Cell Biology - June 27, 2010 Category: Cytology Tags: article Source Type: journals

[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS. Compared with placebo, use of high dose atorvastatin (80 mg/day) for secondary stroke prevention is not only of significant clinical benefit but can also be considered cost effective in Spain. It produces important benefits in health with an incremental cost within reasonable limits. PMID: 20568062 [PubMed - in process] (Source: Revista de Neurologia)
Source: Revista de Neurologia - June 25, 2010 Category: Neurology Authors: Arrospide-Elgarresta A, Mar J, Vivancos-Mora J, Rejas-Gutierrez J, Caro J Tags: Rev Neurol Source Type: journals

Intensive Statin Therapy: A Favorable Adjunct to the Improvement of Small-Diameter Vascular GraftsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, intensive statin therapy could be considered a favorable option to improve small-diameter vascular graft patency. (Source: Angiology)
Source: Angiology - June 25, 2010 Category: Cardiology Authors: Jie Li, , Lu, W.-M., Li, X.-X., Wang, S.-M., Yu, J.-X., Zhu, Y.-F., Liu, D.-Y., Huang, M.-Q. Tags: Articles Source Type: journals

Pfizer Canada Inc. Provides Status on Lipitor Continuity Card Program in QuebecEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
MONTREAL, June 18 /CNW/ - The Regie d'Assurance Maladie du Quebec (RAMQ) recently advised Pfizer that they are examining all pharmaceutical card programs in Quebec. In light of this they have sent us a formal request dated June 16, 2010 to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2010 Category: Pharmaceuticals Source Type: news

Coadministration of fenofibrate does not have a significant effect on the pharmacokinetics of atorvastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - June 21, 2010 Category: Drugs & Pharmacology Tags: Research article Source Type: journals

Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrolleesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study examines whether this adherence benefit results in fewer cardiovascular (CV) events. Methods: A retrospective cohort study was conducted using administrative claims data from the IMS LifeLink: US Health Plan Claims database, identifying adults already taking CCB or statin (but not both) who had an index event of either initiating treatment with SPAA or adding CCB to statin (or vice versa) between April 1, 2004 to August 31, 2005. Inclusion criteria included age 18+ years, continuously enrolled for minimum of 6 months prior and 18 months following treatment initiation, >1 diagnosis of hypertension, and no prescri...
Source: BMC Cardiovascular Disorders - June 17, 2010 Category: Cardiology Authors: Richard ChapmanJason YeawCraig Roberts Source Type: journals

Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Statins are cholesterol-lowering pharmaceuticals and commonly prescribed drugs in European countries. Their discharge into the aquatic environment has increased in the last few years and they are present at detectable levels in most sewage effluents. The aim of the present study was to quantify the cytotoxic effects of acid and lactone forms of two statins, atorvastatin and simvastatin, as well as selected metabolites (ortho- and para-hydroxy atorvastatin acid, ortho-hydroxy atorvastatin lactone, simvastatin hydroxyl carboxylic acid, and 3''hydroxy simvastatin lactone) to hepatocytes from rainbow trout (Oncorhynchus my...
Source: Toxicology in Vitro - June 17, 2010 Category: Toxicology Authors: Ellesat KS, Tollefsen KE, Sberg A, Thomas KV, Hylland K Tags: Toxicol In Vitro Source Type: journals

Affordable Alternatives to Brand Name Atrovastatin are Now Available in CanadaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Canadian online pharmacy service Pharmacy-Online.ca is now able to provide generic atrovastatin, an alternative to Lipitor, to their American patients. (PRWeb Jun 15, 2010) Read the full story at http://www.prweb.com/releases/2010/06/prweb4120654.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 16, 2010 Category: Pharmaceuticals Source Type: news

Atorvastatin/fusidic acid interaction: Rhabdomyolysis and acute renal failure in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - June 13, 2010 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Atorvastatin protects renal function in the rat with acute unilateral ureteral obstructionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: In this particular community-dwelling with an elderly female population, urodynamics is easily feasible. Incontinence, mainly "complicated" is the more frequent complaint and urgency the more frequent symptom. Urodynamic diagnosis underlines the high incidence of detrusor overactivity as well as impaired detrusor function. (Source: International Braz J Urol)
Source: International Braz J Urol - June 12, 2010 Category: Urology & Nephrology Source Type: journals

Effects of atorvastatin on the regeneration of pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To investigate the role of statins in β-cell regeneration a model of streptozotocin (STZ)-induced β-cell injury was used in the neonatal rat. We hypothesized that β-cell growth and regeneration would increase following treatment with atorvastatin and that this would be associated with intraislet vasculogenesis. Pregnant Wistar rats were gavaged with 20 or 40 mg/kg atorvastatin for 21 days commencing on gestation day 15. Atorvastatin was detected in the circulation of the offspring. On postnatal day 4, the pups were given either a control or STZ (70 mg/kg ip) injection. β-Cell mass had partially recovere...
Source: AJP: Endocrinology and Metabolism - June 11, 2010 Category: Endocrinology Authors: Marchand, K. C., Arany, E. J., Hill, D. J. Tags: Articles Source Type: journals

FDA Reprimands Pfizer for Slow Reporting of Adverse EventsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The 12-page letter documents increasing numbers of adverse-event reports that are not being shared with the FDA within the stipulated 15-day window, including adverse reactions to the company's blockbuster statin, Lipitor. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 11, 2010 Category: Consumer Health News Tags: Cardiology News Source Type: news

Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease: A Post Hoc Analysis of Data from a Prospective, Randomized, Double-Blind StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 11, 2010 Category: Drugs & Pharmacology Authors: Walter, ThomasSzabo, SebastianSuselbeck, TimBorggrefe, MartinLang, SiegfriedSwoboda, StefanieHans Martin Hoffmeister,Dempfle, Carl-Erik Tags: Original Research Articles Source Type: journals

Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 geneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The synergy of the effect of mefloquine at concentrations relevant to its achievable plasma concentrations in patients taking 80 mg of atorvastatin daily suggests that atorvastatin will be a good candidate in combination with mefloquine for malaria treatment. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - June 9, 2010 Category: Microbiology Authors: Wurtz, N., Briolant, S., Gil, M., Parquet, V., Henry, M., Baret, E., Amalvict, R., Almeras, L., Rogier, C., Pradines, B. Tags: Original research Source Type: journals

Effects of Atorvastatin and Lisinopril on Endothelial Dysfunction in Patients with Behçet's DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: These findings suggest that atorvastatin and lisinopril improve endothelial functions in Behçet's disease patients. However, large studies are needed to determine the long-term effects of atorvastatin and lisinopril therapy. (Echocardiography, ****;**:1-7) (Source: Echocardiography)
Source: Echocardiography - June 9, 2010 Category: Cardiology Authors: Mehmet Tugrul Inanc, Nihat Kalay, Turgun Heyit, Ibrahim Ozdogru, Mehmet Gungor Kaya, Ali Dogan, Haci Ahmet Kasapkara, Ozgur Gunebakmaz, Murat Borlu, Mikail Yarlıoglues, Abdurrahman Oguzhan Source Type: journals

Ranbaxy unveils cholesterol drug in South AfricaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ranbaxy Laboratories has launched its cholesterol lowering drug atorvastatin, the generic version of the world?s best selling drug Lipitor in South Africa. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 8, 2010 Category: Pharmaceuticals Source Type: news

Ranbaxy launches cholesterol drug in SAfricaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ranbaxy Laboratories, India's largest drugmaker by sales, said on Tuesday its unit had launched atorvastatin, generic form of Pfizer Inc's blockbuster Lipitor cholesterol fighter, in South Africa. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 8, 2010 Category: Pharmaceuticals Source Type: news

Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental modelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract  The present study was planned to investigate the antioxidant, antinociceptive, and anti-inflammatory activities of atorvastatin and rosuvastatin (1, 3 and 10 mg/kg, p.o.) in various animal models. The antinociceptive effect was assessed by chemically- (formalin, acetic acid) and thermally- (hot plate) induced nociception, while anti-inflammatory effect was evaluated using carrageenan-, formaldehyde-induced paw oedema and cotton pellet-induced granuloma. The effect of atorvastatin and rosuvastatin on liver antioxidant enzymes like superoxide dismutase, glutathione, LPO, CAT along with the effect...
Source: Inflammopharmacology - June 8, 2010 Category: Drugs & Pharmacology Tags: Inflammopharmacology Source Type: journals

Atorvastatin/fenofibrate: Rhabdomyolysis and renal impairment: 3 case reportsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - June 7, 2010 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals